HomeMarket NewsTheravance and Mylan Resolve Patent Dispute with Teva Over COPD Drug, Yupelri

Theravance and Mylan Resolve Patent Dispute with Teva Over COPD Drug, Yupelri

Actionable Trade Ideas

always free

Intellectual Property Rights, Copyright, Patent or Trademark Infringement

Credit: Olivier Le Moal

Theravance (NASDAQ:TBPH) and its partner Mylan have reached a settlement in their patent litigation with Teva (NYSE:TEVA). As part of the agreement, Teva has been granted a royalty-free, non-exclusive license to market a generic version of the COPD drug Yupelri in the United States starting from April 23, 2039.

The dispute arose when Theravance and Mylan filed a lawsuit against Teva for attempting to market a generic version of Yupelri, also known as revefenacin, before the drug’s Orange Book-listed patents had expired. The settlement is still pending approval from the US Department of Justice and the Federal Trade Commission, as stated in an SEC filing on Monday.

Yupelri is owned by Theravance and licensed to Mylan, which is now part of Viatris (NASDAQ:VTRS). This medication is specifically used for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.